A German university is active in the field of cochlear implants research. The institute's reseachers developed a novel, patent-pending approach for the diagnosis and treatment of hearing disorders.
The use of complex hearing implants, which has been common up to now, is associated with costly and lengthy treatments. So far, several attempts have been made to compensate hearing loss by the use of costly hearing implants. The offered technology pursues a different approach and focusses on the half-cell channel protein connexin 26 (Cx26) which is crucial for the human hearing.